Program of Supervised Occlusive Aerobic Training in People With Fibromyalgia.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06001034 |
Recruitment Status :
Completed
First Posted : August 21, 2023
Last Update Posted : August 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fibromyalgia | Device: Occlusion training | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 37 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Group 1: Aerobic exercise plus occlusive tool. Group 2: Aerobic exercise without occlusive tool. |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | A 9-week Program of Supervised Occlusive Aerobic Training in People With Fibromyalgia in a Hospital Setting, and Its Impact on Blood/Plasma Variables, Quality of Life and Functional Autonomy. |
Actual Study Start Date : | September 15, 2022 |
Actual Primary Completion Date : | February 5, 2023 |
Actual Study Completion Date : | May 20, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Group 1: Aerobic exercise plus occlusive tool.
Performing low-impact aerobic exercise with an occlusive tool 2 days per week.
|
Device: Occlusion training
Impact of supervised occlusive training for 2 days per week for 10 weeks on quality of life and functional autonomy in participants with fibromyalgia.
Other Name: Occlusive cuffing during aerobic exercise in participants with fibromyalgia |
No Intervention: Group 2: Aerobic exercise without occlusive tool.
Performing low-impact aerobic exercise without an occlusive tool 2 days per week.
|
- Change in Coenzyme Q10 after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]Coenzyme Q10
- Change in total antioxidants after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]TAS
- Change in disease impact questionnaire WPI after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]WPI; score between (0-19). The higher the score, the greater the impact of the disease.
- Change in disease impact questionnaire SSscore after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]SS score; score between (0-3) in the first half. Score between (0-40); between 1-10 (1 point), between 11-24 (2 points), more than 25 (3 points) in the second half. The higher the score, the greater the impact of the disease.
- Change in disease impact questionnaire FIQ after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]FIQ; score between (0-100). The higher the score, the greater the impact of the disease
- Change in disease impact questionnaire MFI-20 after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]MFI-20; (0-60) no fatigue. (60-70), fatigue, lighter or more severe, depending on the depending on the rating closer to 60 or 70 points. (more than 70 points), severe fatigue.
- Change in high density lipoproteins after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]HDL
- Change in low density lipoproteins after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]LDL
- Change in total cholesterol lipoproteins after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]CHOL
- Change in triglycerides after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]TG
- Changes in urea after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]Urea
- Changes in creatinine after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]Creatinine
- Change in gamma-glutamyl transferase after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]GGT
- Change in glutamic-pyruvic transaminase after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]GPT
- Change in glutamic oxaloacetic acid transaminase after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]GOT
- Change in alkaline phosphatase after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]ALP
- Change in funcional test after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period) ]6-minute walking test
- Change in funcional test after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period) ]incremental shuttle walking test
- Change in funcional test after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]30 second chair and stand test
- Change in funcional test after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period) ]Time and go test
- Change in malondialdehyde after a 9-week intervention period. [ Time Frame: Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period). ]MDA (malondialdehyde)
- Change in distance traveled after a 9-week intervention period. [ Time Frame: From week 1 to week 9 of the intervention period. ]Pedometer registration. Immediately after each session from week 1 to 9 of the intervention period. With a total of 18 recordings over the 9 weeks of the intervention period.
- Change in visual pain scale VAS over a 9-week intervention period. [ Time Frame: From week 1 to week 9 of the intervention period. ]Visual pain scale (1-10). 1 being lighter and 10 being more severe. Visual pain scale recording. Before and immediately after each session from week 1 to week 9 of the intervention period. With a total of 36 recordings during the 9 weeks of the intervention period.
- Change in perceived exertion scale BORG over a 9-week intervention period. [ Time Frame: From week 1 to week 9 of the intervention period. ]Perceived exertion scale. (1-10). 1 being lighter and 10 being more severe. Perceived exertion scale recording. Before and immediately after each session from week 1 to week 9 of the intervention period. With a total of 36 recordings during the 9 weeks of the intervention period.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
A patient meets diagnostic criteria for fibromyalgia if the following three conditions are present: (American Rheumatology Association). Wolfe et al., (2010).
- o 1) Widespread Pain Index (WPI) ≥ 7 and Symptom Severity Score (SS Score) ≥ 5 or WPI 3-6 and SS ≥ 9.
- Symptoms have been present, at a similar level, during the last three months.
- The patient has no other pathology that could explain the pain.
- Recent negative COVID-19 test.
Exclusion Criteria:
- Other associated pathologies that may hinder the development of the research.
- Mobility limitations.
- Injuries that add to those of the disease itself and hinder mobility.
- No medical evaluation of the diagnosis of the disease.
- Negative results in the inclusion tests.
- Cardiac pathologies.
- Blood pressure higher than 130-90 mmHg.
- No COVID-19 test.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06001034
Spain | |
Universidad Pablo de Olavide | |
Sevilla, Spain, 41013 |
Principal Investigator: | José Carlos Rodríguez Bautista, PhD currently | Universidad Pablo de Olavide |
Documents provided by José Carlos Rodríguez Bautista, Universidad Pablo de Olavide:
Publications:
Responsible Party: | José Carlos Rodríguez Bautista, PhD currently Sport Sciences in Physical Activity, Health and Quality of Life, Universidad Pablo de Olavide |
ClinicalTrials.gov Identifier: | NCT06001034 |
Other Study ID Numbers: |
1441-23 0560-N-22 ( Other Identifier: PEIBA. Junta de Andalucía. Government of Spain. ) |
First Posted: | August 21, 2023 Key Record Dates |
Last Update Posted: | August 21, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Numeric code to each participant, concealing their personal data at all times. |
Supporting Materials: |
Study Protocol Analytic Code |
Time Frame: | The protocol before the start and the numerical codes at the end of the intervention period. |
Access Criteria: | Shared use only from principal investigator with collaborating investigators of the study. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
occlusive training |
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases |
Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases |